Pharma/ Biotechnology Investments Specialist, Vasuda Capital Management

Dr. Bhavneesh Sharma, MD, MBA

Pharma/ Biotechnology Investments Specialist

Vasuda Capital Management

Equity Bottom-Up

<p>We took another look at the design of the on-going phase 2/3 clinical trial for <a href="https://www.smartkarma.com/entities/10499" target="_blank" data-smartkarma-citation="entities:10499:1">Medgenics Inc (MDGN US)</a> NFC-1, to treat adolescents with attention deficit hyperactivity disorder, ADHD with mGluR+ (metabotropic glutamate receptor positive) mutations. ADHD is about $10 billion per year market in the US. mGluR+ tier 1 and 2 mutations may be seen in 20% of all ADHD patients. Treatment for ADHD with these mutations may represent about $2 to 3 billion per year revenue opportunity in the US alone…</p>

We took another look at the design of the on-going phase 2/3 clinical trial for Medgenics Inc (MDGN US) NFC-1, to treat adolescents with attention deficit hyperactivity disorder, ADHD with mGluR+ (metabotropic glutamate receptor positive) mutations. ADHD is about $10 billion per year market in the US. mGluR+ tier 1 and 2 mutations may be seen in 20% of all ADHD patients. Treatment for ADHD with these mutations may represent about $2 to 3 billion per year revenue opportunity in the US alone…

Actionable Idea: Medgenics: Upcoming Catalyst, Recent Insider Buying, Huge Potential Market in ADHD.

United States

Aevi Genomic Medicine, Inc. operates as a biotechnology company. The Company focuses on translating genetic discoveries into novel therapies to improve the lives of children and adults. Aevi Genomic Medicine offers its services in the United States.

Actionable Idea: Medgenics: Upcoming Catalyst, Recent Insider Buying, Huge Potential Market in ADHD.

We took another look at the design of the on-going phase 2/3 clinical trial for Medgenics Inc (MDGN US) NFC-1, to treat adolescents with attention...

Dr. Bhavneesh Sharma, MD, MBA